actinium logoActinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), Actinium is developing two radioimmunotherapy (RIT) drugs based on its APIT drug delivery platform. Iomab-B is being developed for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT) in relapsed and refractory AML patients age of 55 or older. The company is currently preparing for Phase III trial with Iomab-B. Its other product is Actimab-A, an antibody-drug construct containing iodine-131 used in myeloconditioning for HSCT in various indications. Actimab-A consists of mAb lintuzumab and alpha-emitting radioisotope actinium-225 (Ac-225). In November 2014, the FDA granted Orphan Drug designation for Actimab-A.

ATNM is collaborating with Fred Hutchinson Cancer Research Center (FHCRC) and Memorial Sloan Kettering Cancer Center (MSKCC) on its various programs. It also has IP collaboration with AbbVie (NYSE:ABBV). FHCRC has deep expertise in bone marrow transplantation research, and has Dr. E. Donnall Thomas who received the 1990 Nobel Prize in physiology/medicine for work in this area.